
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and ...
Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disorders First-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from …